Poster
Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion‒positive solid tumors: update from the ARROW trial
Author
Vivek Subbiah
Condition
RET fusion‒positive solid tumors
Drug target
RET
Drug moa
RET inhibitor
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicine-ASCO-2021-Pralsetinib-Solid-Tumors-ARROW-Poster.pdf
5 organizations
1 product
Product
PralsetinibOrganization
Blueprint MedicinesOrganization
University of Miami Health SystemOrganization
Fudan University Shanghai Cancer CenterOrganization
University of Texas MD Anderson Cancer CenterOrganization
Mayo Clinic Hospital